Streetbeat News

Products Services

SAVA

Cassava Sciences, Inc. (NASDAQ:SAVA) announced a significant safety finding based on interim MRI brain data from Alzheimer's patients enrolled in a Phase 3 clinical trial of simufilam. The data suggests that simufilam is not associated with amyloid-related imaging abnormalities (ARIA), a known risk factor for Alzheimer's patients taking anti-amyloid antibody drugs. The safety finding is based on an independent, interim neuroradiological evaluation of brain MRIs taken at week 40 in a blinded sub-study of 180 Alzheimer's patients.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:17 pm

BCTX

BriaCell Therapeutics Corp. (NASDAQ:BCTX) has formed a medical advisory board and appointed three distinguished breast cancer specialists to advance its lead oncology candidate. The board includes Massimo Cristofanilli, MD, FACP, Sara A. Hurvitz, MD, FACP, and Adam M. Brufsky, MD, PhD. Charles Sidman, PhD, MBA, has also been added to its scientific advisory board. The company believes that these appointments will provide invaluable insights for their pivotal Phase 3 registration study.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:16 pm

EDSA

Health Canada has approved Edesa Biotech's proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart).

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:15 pm

SNSE

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) will present initial safety and pharmacokinetic clinical data from its Phase 1/2 trial of SNS-101, a cancer therapy, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in November 2023. The presentation will focus on the safety, tolerability, and pharmacokinetics of SNS-101 as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:11 pm

TLSI

TriSalus Life Sciences (NASDAQ:TLSI) will present new data from its clinical development pipeline at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The presentations will include data on liver metastases and pancreatic cancer, and will feature the company's novel delivery technology integrated with immunotherapy.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:09 pm

AAPL

Apple is considering using its upcoming Vision Pro mixed-reality headset as a tool for diagnosing and treating mental health issues. The device's cameras and sensors could measure a person's facial expressions to detect depression, anxiety, stress, or post-traumatic stress disorder. However, marketing medical functions in devices requires regulatory approval.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:04 pm

JNVR

Janover Inc (NASDAQ:JNVR) has announced the addition of new outbound features to its AI platform, including autonomous agents for prospecting and servicing new customers. The company also launched a standalone AI chatbot interface, chat.janover.co, optimized for business development and lead generation. The AI-based agent operates via chat, voice, text, and email, facilitating complex conversations regarding commercial and multifamily real estate finance and SBA lending. The new features are expected to generate new business, re-engage existing customers, and enhance user experience at a lower cost.

Portfolio Pulse from Anusuya Lahiri

October 25, 2023 | 1:01 pm

BK

BNY Mellon (NYSE:BK) has launched Universal FX, a new foreign exchange (FX) platform that allows clients to manage execution across their entire portfolio and provides market-leading price transparency. The platform supports BNY Mellon clients across all market segments and helps them navigate the industry transition to T+1 settlement. The new offering builds on BNY Mellon's OneFX suite of solutions and banking capabilities for all FX trading, FX hedging and cross-border payment activities.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:01 pm

JNVR

Janover Co. has launched enhanced AI capabilities focused on business development and a standalone chatbot interface. The new technology is expected to improve customer service and increase efficiency.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 1:00 pm

INTU

BILL has extended new purchase order capabilities for small and midsize businesses and accountants to enhance control over financial workflows. The new purchase order automation from BILL streamlines processes for Intuit QuickBooks Desktop customers, including QuickBooks Enterprise, QuickBooks Premier, and QuickBooks Pro. Customers can now view purchase orders, match and pay invoices in one workspace, and sync purchase order and receipt details from QuickBooks Desktop to BILL.

Portfolio Pulse from Benzinga Newsdesk

October 25, 2023 | 12:59 pm